Ethyl dirazepate[1] is a drug which is a benzodiazepine derivative which was developed by Sanofi Winthrop. It has anxiolytic and hypnotic and possibly other characteristic benzodiazepine properties.[2][3][4]

Ethyl dirazepate
Identifiers
  • ethyl 7-chloro-5-(2-chlorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepine-3-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H14Cl2N2O3
Molar mass377.22 g·mol−1
3D model (JSmol)
  • CCOC(=O)C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3Cl
  • InChI=1S/C18H14Cl2N2O3/c1-2-25-18(24)16-17(23)21-14-8-7-10(19)9-12(14)15(22-16)11-5-3-4-6-13(11)20/h3-9,16H,2H2,1H3,(H,21,23) ☒N
  • Key:XFVPZJMXRNBHLQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

See also

edit

References

edit
  1. ^ ZA Patent 6804601
  2. ^ "ethyl dirazepate". psychotropics.dk. 2003. Retrieved 7 December 2009.
  3. ^ "Drugs of the Future". Thomson Reuters. 6 (11). November 1981.
  4. ^ "LIST OF INTERNATIONAL NON-PROPRIETARY NAMES (INNS), PROVIDED FOR PHARMACEUTICAL SUBSTANCES BY THE WORLD HEALTH ORGANIZATION, WHICH ARE FREE OF DUTY". Official Journal of the European Communities. eur-lex.europa.eu. 23 October 2001. Archived from the original (PDF) on 27 June 2014. Retrieved 7 December 2009.